glutamine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1311 56-85-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • L-Glutamine
  • glutamine
  • glutamic acid amide
  • L-(+)-Glutamine
  • L-2-Aminoglutaramidic acid
  • levoglutamide
A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.
  • Molecular weight: 146.15
  • Formula: C5H10N2O3
  • CLOGP: -3.37
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 3
  • TPSA: 106.41
  • ALOGS: -0.17
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
June 10, 2004 FDA EMMAUS MEDCL

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sickle cell anaemia with crisis 37.67 22.31 10 998 3982 46681072

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tendon calcification 37.56 28.04 5 638 42 29951793

Pharmacologic Action:

SourceCodeDescription
ATC A16AA03 ALIMENTARY TRACT AND METABOLISM
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
Amino acids and derivatives
FDA CS M0000922 Amino Acids
FDA EPC N0000175780 Amino Acid
CHEBI has role CHEBI:27027 trace elements
CHEBI has role CHEBI:50733 nutritional supplement
CHEBI has role CHEBI:61908 ec 1.14.13.39 inhibitors
CHEBI has role CHEBI:75771 mus musculus metabolite
CHEBI has role CHEBI:75772 baker's yeast metabolite
CHEBI has role CHEBI:76971 e.coli metabolites
CHEBI has role CHEBI:77746 h. sapiens metabolites
CHEBI has role CHEBI:78675 essential metabolite
CHEBI has role CHEBI:25212 metabolites

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Short bowel syndrome indication 26629001 DOID:10605
Hb SS disease symptomatic treatment 127040003 DOID:10923

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.17 acidic
pKa2 12.12 acidic
pKa3 9.22 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
5GM/PACKET ENDARI EMMAUS MEDCL N208587 July 7, 2017 RX FOR SOLUTION ORAL July 7, 2024 TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS 5 YEARS OF AGE AND OLDER.

Bioactivity Summary:

None

External reference:

IDSource
4027901 VUID
N0000177918 NUI
4025874 VANDF
4027901 VANDF
C0017797 UMLSCUI
CHEBI:18050 CHEBI
GLN PDB_CHEM_ID
CHEMBL930 ChEMBL_ID
DB00130 DRUGBANK_ID
D005973 MESH_DESCRIPTOR_UI
723 IUPHAR_LIGAND_ID
1413 INN_ID
0RH81L854J UNII
5961 PUBCHEM_CID
4885 RXNORM
12067 MMSL
158599 MMSL
158601 MMSL
d07315 MMSL
000928 NDDF
25761002 SNOMEDCT_US
412421007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Endari HUMAN PRESCRIPTION DRUG LABEL 1 42457-420 POWDER, FOR SOLUTION 5 g ORAL NDA 26 sections